ACHA has been awarded $185,000 from three separate grants. The funds were given to the organization to support our existing programs and campaigns that seek to extend and improve the lives of people living with congenital heart disease.
The Medtronic Foundation awarded ACHA a two-year, $120,000 grant to support our ongoing “Don’t Get Lost” campaign, which increases communication and outreach to adults with congenital heart disease. Over the course of this two-year grant, we aim to increase our patient/family membership numbers by 25%, increase the value of our website by growing the number of pageviews by 25%, and increase member engagement by growing the amount of patient/family members who donate to ACHA by 25%.
Actelion Pharmaceuticals US, Inc. awarded ACHA with a $50,000 grant, and Gilead Sciences, Inc. awarded ACHA with a $15,000 grant. Both grants will support the our Heart to Heart (H2H) program through 2012, which provides adults with congenital heart disease a toolkit of resources with the information and skills they need to thrive.
The toolkit includes online resources, educational events, and peer support programs. Actelion’s support will enable ACHA to train 12 new H2H Ambassadors, fund additional publications, and conduct up to eight webinars on congenital heart disease topics. Gilead’s support will fund general expenses related to the H2H program, including the development and disbursement of educational materials, webinars, and other program-related materials.
“ACHA is tremendously grateful to our corporate partners for their ongoing commitment to improving and prolonging the lives of every person born with a heart defect,” says ACHA President/CEO Amy Verstappen. “This support will help us reach out to congenital heart patients and families and provide them with the health and information they need to thrive.”